1 / 10

Table 1. Clinicopathological findings at biopsy

Table 1. Clinicopathological findings at biopsy. Clinical Number of patients Age (years) Gender (%Male) eGFR (ml/min/1.73m 2 ) UPE (g/day) Serum albumin (g/dl) Hypertension (%) Histopathological Total cortical area Total glomerular number

gabby
Download Presentation

Table 1. Clinicopathological findings at biopsy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Table 1. Clinicopathological findings at biopsy Clinical Number of patients Age (years) Gender (%Male) eGFR (ml/min/1.73m2) UPE (g/day) Serum albumin (g/dl) Hypertension (%) Histopathological Total cortical area Total glomerular number Global glomerular sclerosis (%) Segmental glomerular sclerosis (%) IF/TA; semi-quantitative (%) IF/TA; quantitative (%) GD (/mm2) 65 56±14 (15～84) 68 80±19 (60～141) 3.1±2.4 (0.3～13.4) 3.2±0.7 (1.7～4.6) 38 5.9±2.7 (1.9～14.1) 25±11 (10～58) 5.1±6.3 (0～30) 0.7±2.6 (0～17) 9.0±6.0 (0～27.7) 11.2±8.1 (0～37.1) 3.4±1.1 (1.6～6.5) UPE: Urinary protein excretion, IF/TA: Interstitial fibrosis/tubular atrophy, GD: Glomerular density

  2. Table 2. Clinical findings during the follow-up Duration of follow-up (years) Therapies during the follow-up Immunosuppressants (%) ACE-I/ARB (%) Last observation UPE (g/day) UPE >1g/day (%) eGFR (ml/min/1.73m2) 　　⊿eGFR (%/years) > 50% reduction in eGFR (%) ESRD (%) 8.1±3.8 (5～24) 42 86 1.7±2.5 (0.0～9.2) 40 61±28 (3～129) -3.8±5.6 (-32.8～2.8) 15 8 UPE: Urinary protein excretion, ESRD: End-stage renal disease

  3. Table 3. Comparison of the clinicopathological findings and renal outcome between the patients with lower GD (<3.1 /mm2) and those with higher GD (>3.1 /mm2) GD <3.1/mm2 (n= 33) 55±14 80±21 3.2±2.2 33 33 6.1±5.6 1.2±3.6 9.3±5.4 12.1±7.7 7.8±3.4 42 88 55 -5.4±6.9 27 GD >3.1 /mm2 (n=32) 56±14 79±17 3.0±2.5 31 41 4.1±6.8 0.2±0.9 8.6±6.1 10.2±8.6 8.4±4.2 41 81 25 -2.2±3.5 3 P value 0.748 0.942 0.778 0.857 0.543 0.059 0.232 0.244 0.151 0.586 0.883 0.459 0.015 0.034 0.007 At biopsy Age eGFR (ml/min/1.73m2) UPE (g/day) UPE >3.5g/day (%) Hypertension (%) Global glomerular sclerosis (%) Segmental glomerular sclerosis (%) IF/TA; semi-quantitative (%) IF/TA; quantitative (%) Follow-up Duration of follow-up Therapies during the follow-up Immunosuppressants (%) ACE-I/ARB (%) Last observation UPE >1g/day (%) ⊿eGFR (%/years) >50% reduction in eGFR or ESRD (%) UPE: Urinary protein excretion, IF/TA: Interstitial fibrosis/tubular atrophy, ESRD: End-stage renal disease.

  4. Table 4. Factors at biopsy influencing slope in renal function (⊿eGFR) by univariate and multivariate regression analyses Univariate Multivariate Variables Age (years) eGFR (ml/min/1.73m2) MAP (mmHg) UPE (g/day) * * Serum albumin (g/dl) Global glomerular sclerosis (%) ** Segmental glomerular sclerosis (%) * IF/TA; quantitative (%) GD (/mm2) r -0.200 0.145 -0.134 -0.112 0.130 -0.134 -0.119 0.127 0.319 p 0.110 0.249 0.288 0.375 0.303 0.286 0.345 0.313 0.010 t -1.114 0.259 -0.532 -0.609 0.678 0.259 -0.529 0.313 2.286 p 0.270 0.797 0.597 0.545 0.501 0.796 0.599 0.755 0.026 MAP: Mean arterial pressure, UPE: Urinary protein excretion, IF/TA: Interstitial fibrosis/tubular atrophy, GD: Glomerular density, * Variables were log-transformed before analysis.

  5. Patients with >50% reduction in eGFR or ESRD % 60 50 40 30 20 10 0 • 15 8 24 Number of patients + - + - Proteinuria >1g/day at follow-up Lower (3.1>) Higher (3.1< ) GD (mm2) Figure 1

  6. Figure 2 10 0 -10 ⊿eGFR (%/yr) -20 n=65 r=0.319 p=0.010 -30 -40 0 1 2 3 4 5 6 7 8 GD (/mm2)

  7. Table S1. Comparison of the clinicopathological findings and renal outcome between the patients with lower GD (<3.1 /mm2) and those with higher GD (>3.1 /mm2) treated with immunosupplessants GD<3.1/mm2 (n= 14) 58±8 75±12 57 21 6.1±5.2 2.0±5.2 10.6±6.4 13.9±6.9 7.5±2.9 100 93 64 -7.2±4.9 43 GD>3.1 /mm2 (n=13) 53±13 79±14 46 54 2.5±3.4 0.2±0.8 8.5±6.4 9.8±9.1 8.6±5.3 100 85 31 -3.0±4.9 8 P value 0.550 0.402 0.568 0.081 0.054 0.756 0.302 0.038 0.943 - 0.456 0.082 0.009 0.037 At biopsy Age eGFR (ml/min/1.73m2) UPE >3.5g/day (%) Hypertension (%) Global glomerular sclerosis (%) Segmental glomerular sclerosis (%) IF/TA; semi-quantitative (%) IF/TA; quantitative (%) Follow-up Duration of follow-up Therapies during the follow-up Immunosuppressants (%) ACE-I/ARB (%) Last observation UPE >1g/day (%) 　　⊿eGFR (%/years) >50% reduction in eGFR or ESRD (%) UPE: Urinary protein excretion, IF/TA: Interstitial fibrosis/tubular atrophy, ESRD: End-stage renal disease

  8. Table S2. Glomerular density and renal outcome in relation to interstitial fibrosis and segmental glomerular sclerosis Interstitial fibrosis/ tubular atrophy >10% (n=34) <10% (n=31) >20% (n=10) <20% (n=55) Segmental glomerular sclerosis Present (n=7) Absent (n=58) GD ( /mm2) 3.0±0.7 3.8±1.2 2.8±1.0 3.5±1.1 3.1±1.2 3.4±1.1 p value 0.010 0.037 0.478 >50% reduction in eGFR (%) 21 10 30 13 29 16 p value 0.223 0.164 0.384 ⊿eGFR (%/year) -4.5±4.9 -3.0±6.4 -5.0±4.2 -3.6±5.9 -4.6±5.2 -3.7±5.7 p value 0.136 0.260 0.682

  9. 40 35 30 25 20 15 IF/TA quantitative (%) 10 n=65 r=0.781 P<0.0001 5 0 -5 -5 0 5 10 15 20 25 30 IF/TA semi-quantitative (%) Figure S1

  10. Figure S2 8 7 /m2 6 5 4 3 Glomerular density (simple measuring) 2 n=65 r=0.888 p<0.0001 1 1 2 3 4 5 6 7 /m2 Glomerular density (imaging analysis)

More Related